Home  /  Resource Library  /  Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Study investigated nivolumab combined with brentuximab vedotin and bendamustine for treatment of relapsed pediatric Hodgkin lymphoma.